Novo Nordisk files for liraglutide approval in Japan
COPENHAGEN, July 15 |
COPENHAGEN, July 15 (Reuters) - Denmark's Novo Nordisk (NOVOb.CO), the world's biggest maker of insulin, said on Tuesday it filed for regulatory approval for its diabetes drug liraglutide in Japan.
The drug, a once daily insulin analogue, treats people with type 2 diabetes. It works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite, also leading to weight loss.
(Reporting by Gelu Sulugiuc; Editing by Quentin Bryar)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters